Acquisition
canadiense solar inc.
€0.00
07:46 20/03/24
Halma plc ('Halma' o el 'Grupo')
Acquisition
Halma, the global group of life-saving technology companies, today announces that it has acquired Rovers Medical Devices B.V. ("Rovers").
Headquartered in Oss in the Netherlands, Rovers designs and manufactures sample collection devices used in the prevention and diagnostics of cervical cancer. Rovers' products are principally for professional use and include its Cervex-Brush®, widely recognised as the gold standard for cervical cancer screening. Rovers' products are used in more than 90 countries, and are sold primarily to medical diagnostic companies, as well as medical distributors, laboratories, research institutes and governments.
The initial consideration for Rovers is ?85m (approximately £73m), on a cash- and debt-free basis, which will be paid in cash and funded from Halma's existing facilities. An additional consideration of up to ?6m (approximately £5m) is payable in cash, based on Rovers' performance in the period to 31 March 2025.
Rovers' unaudited revenue for the 12 months to 31 December 2023 was ?12.0m (approximately £10.3m), with Return on Sales more than double Halma's target range of 18-22%. Rovers will be a standalone company within Halma's Healthcare sector, led by its current management team.
Marc Ronchetti, Group Chief Executive of Halma, said:
"Rovers will broaden the range of markets we serve in women's health and further strengthen our Healthcare sector's position in cancer diagnosis products. We are excited by the opportunities we see to increase Rovers' positive impact on public health. We expect its future growth to be driven by increasing global cervical screening rates, supporting the World Health Organization's strategy to accelerate the early detection of cervical cancer."
Roel Leenders, Chief Executive Officer of Rovers, said:
"We want to contribute to the prevention of cancer on a global scale. This mission strongly aligns to Halma's when it comes to improving quality of care for patients. Many physicians work with us to develop the highest quality screening products that are most effective for their patients. By joining the Halma group, Rovers can grow to the next level, adding talent development and commercial opportunities while collaborating with a global group of like-minded businesses, that will help us to enable better screening and diagnostics for patients worldwide."
Para más información, por favor póngase en contacto con:
halma plc
Marc Ronchetti, director ejecutivo del grupo 44 0 1494
Steve Gunning, director financiero del grupo
Charles King, Jefe de Relaciones con Inversores +44 (0) 7776 685948
Clayton Hirst, director de asuntos corporativos +44 0 7384 796 013
MHP
Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100
Una copia de este anuncio, junto con otra información sobre Halma, está disponible en www.halma.com.
Sobre Halma
Halma es un grupo global de empresas de tecnología que salvan vidas, enfocado en hacer crecer un futuro más seguro, limpio y saludable para todos, todos los días. Su propósito define los tres grandes mercados en los que opera:
· Salud: satisfacer la creciente demanda de una mejor atención médica a medida que aumentan las enfermedades crónicas, impulsadas por el crecimiento y el envejecimiento de la población y los cambios en el estilo de vida.
· Medio ambiente: abordar los impactos del cambio climático, la contaminación y los desechos, proteger los recursos críticos para la vida y apoyar la investigación científica.
· Safety - Protecting people's safety and the environment as populations grow and enhancing worker safety.
Emplea a más de 8,000 personas en más de 20 países, con operaciones importantes en el Reino Unido, Europa continental, EE. UU. Y Asia Pacífico. Halma cotiza en la Bolsa de Valores de Londres (LON: HLMA) y es un componente del índice FTSE 100.
Halma ha sido nombrada una de las empresas más admiradas de Gran Bretaña durante los últimos cinco años.
Para más información www.halma.com
EXTREMOS
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.